These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36205301)

  • 1. Identification of an m6A-related lncRNA prognostic signature in colorectal cancer.
    Shi ZL; Yang X; Shen CL; Zhou GQ
    J Biochem Mol Toxicol; 2023 Jan; 37(1):e23239. PubMed ID: 36205301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
    Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer.
    Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH
    Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of an N6-methyladenosine lncRNA- and immune cell infiltration-related prognostic model in colorectal cancer.
    Yu ZL; Zhu ZM
    Protoplasma; 2022 Jul; 259(4):1029-1045. PubMed ID: 34734333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity.
    Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L
    Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696
    [No Abstract]   [Full Text] [Related]  

  • 6. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
    Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C
    BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. lncRNAs AC156455.1 and AC104532.2 as Biomarkers for Diagnosis and Prognosis in Colorectal Cancer.
    Kuang F; Luo D; Zhou M; Du J; Yang J
    Dis Markers; 2022; 2022():4872001. PubMed ID: 36277972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of N6-methylandenosine related lncRNA signatures for predicting the prognosis and therapy response in colorectal cancer patients.
    Li Z; Liu Y; Yi H; Cai T; Wei Y
    Front Genet; 2022; 13():947747. PubMed ID: 36246627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
    Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
    Front Immunol; 2022; 13():951455. PubMed ID: 36189298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
    Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
    J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of N6-methylandenosine regulators and m6A-related RNAs as prognosis factors in colorectal cancer.
    Li W; Gao Y; Jin X; Wang H; Lan T; Wei M; Yan W; Wang G; Li Z; Zhao Z; Jiang X
    Mol Ther Nucleic Acids; 2022 Mar; 27():598-610. PubMed ID: 35070494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients.
    Wang JM; Li X; Yang P; Geng WB; Wang XY
    BMC Gastroenterol; 2022 Feb; 22(1):76. PubMed ID: 35189810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
    Liu Y; Wang T; Fang Z; Kong J; Liu J
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N6-methyladenosine-related lncRNAs is a potential marker for predicting prognosis and immunotherapy in ovarian cancer.
    Nie X; Tan J
    Hereditas; 2022 Mar; 159(1):17. PubMed ID: 35303965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Validation of a Novel 2-LncRNAs Signature Associated with m6A Regulation in Colorectal Cancer.
    Wang K; Zhao B; Liang Y; Ma B
    J Cancer; 2022; 13(1):21-33. PubMed ID: 34976168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 19. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
    BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Nine M6A-Related Long Noncoding RNAs as Prognostic Signatures Associated with Oxidative Stress in Oral Cancer Based on Data from The Cancer Genome Atlas.
    Shan L; Lu Y; Song Y; Zhu X; Xiang CC; Zuo ED; Cheng X
    Oxid Med Cell Longev; 2022; 2022():9529814. PubMed ID: 35910847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.